Vanta Bioscience Ltd Stock Price Today (NSE: VANTABIO)
Vanta Bioscience Ltd
Fundamental Score
Vanta Bioscience Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Vanta Bioscience Ltd share price today is ₹20.30, up +0.00% on NSE/BSE as of 19 February 2026. Vanta Bioscience Ltd (VANTABIO) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹16.84 (Cr). The 52-week high for VANTABIO share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of -37.24% and a debt-to-equity ratio of 1.59.
Vanta Bioscience Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vanta Bioscience Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vanta Bioscience Share Price: A Risk Management Perspective
The healthcare research, analytics, and technology sector is currently witnessing a surge in demand for specialized contract research organizations (CROs), driven by pharmaceutical companies seeking to streamline drug development processes and reduce costs. This analysis focuses on Vanta Bioscience share price (₹19.5), offering a risk management perspective based on publicly available financial data. This is part of an 80-parameter fundamental audit, verified by Sweta Mishra, and solely provides an observational analysis, not a recommendation to buy or sell.
A crucial element of this risk assessment is the company's profitability, or lack thereof, as highlighted by its Return on Capital Employed (ROCE) of -11.58%. This negative ROCE indicates that Vanta Bioscience is currently destroying value with the capital it employs. In contrast to
NOVELIX PHARMACEUTICALS LIMITE, whose management team has demonstrated consistent improvement in operational efficiency, Vanta Bioscience's negative ROCE raises questions about its operational effectiveness and strategic direction.The absence of a Price-to-Earnings (PE) ratio further underscores the company's current lack of profitability. This missing metric prevents a standard valuation comparison with sector peers such as Suven Life Sciences Ltd and Syngene International Ltd. While these peers may have their own challenges, the lack of earnings for Vanta Bioscience presents a significantly higher risk profile for potential investors. A sustainable competitive advantage, or "moat," is often built on superior financial performance. A consistently negative ROCE of -11.58% significantly erodes any potential moat, making it difficult for Vanta Bioscience to generate sustainable profits and attract investor confidence.
Therefore, the negative ROCE raises concerns about the long-term financial stability of Vanta Bioscience and its ability to compete effectively within the CRO sector. Further investigation into the underlying reasons for this negative performance, including cost structure, revenue generation, and capital allocation, is warranted to fully assess the risks associated with Vanta Bioscience share price.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vanta Bioscience Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VANTABIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.81%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-37.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-11.58%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-70.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-32.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.59)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-2.69x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-43.40 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vanta Bioscience Ltd Financial Statements
Comprehensive financial data for Vanta Bioscience Ltd including income statement, balance sheet and cash flow
About VANTABIO (Vanta Bioscience Ltd)
Vanta Bioscience Ltd (VANTABIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Research, Analytics & Technology sector with a current market capitalisation of ₹16.84 (Cr). Vanta Bioscience Ltd has delivered a Return on Equity (ROE) of -37.24% and a ROCE of -11.58%. The debt-to-equity ratio stands at 1.59, reflecting the company's capital structure. Investors tracking VANTABIO share price can monitor key metrics including P/E ratio, promoter holding of 72.81%, and quarterly earnings growth.
Company Details
Key Leadership
VANTABIO Share Price: Frequently Asked Questions
What is the current share price of Vanta Bioscience Ltd (VANTABIO)?
As of 19 Feb 2026, 10:23 am IST, Vanta Bioscience Ltd share price is ₹20.30. The VANTABIO stock has a market capitalisation of ₹16.84 (Cr) on NSE/BSE.
Is VANTABIO share price Overvalued or Undervalued?
VANTABIO share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 45.95x. Based on this relative valuation, the Vanta Bioscience Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of VANTABIO share price?
The 52-week high of VANTABIO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Vanta Bioscience Ltd share price?
Key factors influencing VANTABIO share price include quarterly earnings growth (Sales Growth: -70.87%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vanta Bioscience Ltd a good stock for long-term investment?
Vanta Bioscience Ltd shows a 5-year Profit Growth of N/A% and an ROE of -37.24%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.59 before investing in VANTABIO shares.
How does Vanta Bioscience Ltd compare with its industry peers?
Vanta Bioscience Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare VANTABIO share price P/E of 0.00x and ROE of -37.24% against the industry averages to determine competitive standing.
What is the P/E ratio of VANTABIO and what does it mean?
VANTABIO share price has a P/E ratio of N/Ax compared to the industry average of 45.95x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is VANTABIO performing according to Bull Run's analysis?
VANTABIO has a Bull Run fundamental score of 7.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VANTABIO belong to?
VANTABIO operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vanta Bioscience Ltd share price.
What is Return on Equity (ROE) and why is it important for VANTABIO?
VANTABIO has an ROE of -37.24%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vanta Bioscience Ltd generates profits from shareholders capital.
How is VANTABIO debt-to-equity ratio and what does it indicate?
VANTABIO has a debt-to-equity ratio of 1.59, which indicates high leverage that increases financial risk.
What is VANTABIO dividend yield and is it a good dividend stock?
VANTABIO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vanta Bioscience Ltd shares.
How has VANTABIO share price grown over the past 5 years?
VANTABIO has achieved 5-year growth rates of: Sales Growth -32.27%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in VANTABIO and why does it matter?
Promoters hold 72.81% of VANTABIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vanta Bioscience Ltd.
What is VANTABIO market capitalisation category?
VANTABIO has a market capitalisation of ₹17 crores, placing it in the Small-cap category.
How volatile is VANTABIO stock?
VANTABIO has a beta of N/A. A beta > 1 suggests the Vanta Bioscience Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VANTABIO operating profit margin trend?
VANTABIO has a 5-year average Operating Profit Margin (OPM) of 5.69%, indicating the company's operational efficiency.
How is VANTABIO quarterly performance?
Recent quarterly performance shows Vanta Bioscience Ltd YoY Sales Growth of -70.87% and YoY Profit Growth of 12.08%.
What is the institutional holding pattern in VANTABIO?
VANTABIO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vanta Bioscience Ltd stock.